tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Vamil Divan, 238 are a BUY (65.38%), 113 are a HOLD (31.04%), 13 are a SELL (3.57%).
Analyst Vamil Divan, currently employed at GUGGENHEIM, carries an average stock price target met ratio of 63.44% that have a potential upside of 30.65% achieved within 265 days.
Vamil Divan’s has documented 739 price targets and ratings displayed on 47 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ABBV, AbbVie at 19-Oct-2025.
Analyst best performing recommendations are on ARAV (ARAVIVE).
The best stock recommendation documented was for KRTX (KARUNA THERAPEUTICS) at 8/9/2022. The price target of $276 was fulfilled within 3 days with a profit of $47.55 (20.81%) receiving and performance score of 69.38.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$242
$14.01 (6.15%)
$216
8 days ago
(19-Oct-2025)
27/28 (96.43%)
$9.94 (4.28%)
437
Buy
$250
$22.01 (9.65%)
$220
11 days ago
(16-Oct-2025)
13/14 (92.86%)
$20.43 (8.90%)
399
Buy
$284
$56.01 (24.57%)
$220
18 days ago
(09-Oct-2025)
43/44 (97.73%)
$53.5 (23.21%)
593
Hold
$251
$23.01 (10.09%)
$205
25 days ago
(02-Oct-2025)
15/16 (93.75%)
$17.09 (7.31%)
300
Buy
$270
$42.01 (18.43%)
$195
1 months 11 days ago
(16-Sep-2025)
2/3 (66.67%)
$49.19 (22.28%)
121
Which stock is Vamil Divan is most bullish on?
Which stock is Vamil Divan is most reserved on?
What Year was the first public recommendation made by Vamil Divan?
